Considerations for Design, Development, and Analytical Validation of Next Generation Sequencing (NGS) - Based In Vitro Diagnostics (IVDs) Intended to Aid in the Diagnosis of Suspected Germline Diseases Guidance for Stakeholders and Food and Drug Administration Staff April 2018
- Docket Number:
- Issued by:
Guidance Issuing OfficeCenter for Devices and Radiological Health
The field of genomic testing is dynamic, building off of increasing amounts of data and a rapidly evolving technology base. While current regulatory approaches are appropriate for conventional diagnostics that measure a limited number of analytes associated with a disease or condition, the new sequencing technologies used in genomic testing can examine millions of DNA variants at a time, and thus warrant a flexible approach to oversight that is adapted to the novel and evolving nature of these tests. The Agency’s intent is to optimize its approach to regulatory oversight for Next Generation Sequencing (NGS) in vitro diagnostic (IVD) tests to support the needs of the rapidly evolving novel technologies in genomic medicine while at the same time meeting its critical mandate to ensure that medical devices have a reasonable assurance of safety and effectiveness.
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2016-D-1270.